Underutilization of anthracyclines in the management of HER2-overexpressing advanced breast cancer patients

被引：0
|
作者：
Montemurro, F.
Redana, S.
Valabrega, G.
Donadio, M.
Jacomuzzi, M. E.
Vietti-Ramus, G.
Clavarezza, M.
Danese, S.
Durando, A.
Venturini, M.
Aglietta, M.
机构：
[1] Inst Canc Res & Treatment, Candiolo, Italy
[2] Molinette Mauriziano Hosp, Ctr Oncol Subalpino COES, Turin, Italy
[3] Mauriziano Hosp, Turin, Italy
[4] Giovanni Bosco Hosp, Turin, Italy
[5] Ist Nazl Tumori, Senol Dis Management Team, Genoa, Italy
[6] St Anna Hosp, Turin, Italy
来源：
ANNALS OF ONCOLOGY | 2006年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：XI9 / XI10
页数：2
相关论文
共 50 条
  • [1] Activity of fulvestrant in HER2-overexpressing advanced breast cancer
    Robertson, J. F. R.
    Steger, G. G.
    Neven, P.
    Barni, S.
    Gieseking, F.
    Nole, F.
    Pritchard, K. I.
    O'Malley, F. P.
    Simon, S. D.
    Kaufman, B.
    Petruzelka, L.
    ANNALS OF ONCOLOGY, 2010, 21 (06) : 1246 - 1253
  • [2] Treatment of HER2-overexpressing breast cancer
    Baselga, J.
    ANNALS OF ONCOLOGY, 2010, 21 : 36 - 40
  • [3] Target Therapy in HER2-Overexpressing Breast Cancer Patients
    Amodio, Rosalba
    Zarcone, Maurizio
    Cusimano, Rosanna
    Campisi, Ildegarda
    Dolcemascolo, Cecilia
    Traina, Adele
    Agostara, Biagio
    Romano, Nino
    OMICS-A JOURNAL OF INTEGRATIVE BIOLOGY, 2011, 15 (06) : 363 - 367
  • [4] Lapatinib for the treatment of HER2-overexpressing breast cancer
    Jones, J.
    Takeda, A.
    Picot, J.
    von Keyserlingk, C.
    Clegg, A.
    HEALTH TECHNOLOGY ASSESSMENT, 2009, 13 : 1 - 6
  • [5] Pertuzumab: evolving therapeutic strategies in the management of HER2-overexpressing breast cancer
    O'Sullivan, Ciara C.
    Swain, Sandra M.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2013, 13 (05) : 779 - 790
  • [6] Capecitabine and trastuzumab: a phase II study in HER2-overexpressing metastatic breast cancer (MBC) patients pretreated with anthracyclines and/or taxanes
    Schaller, G
    Bangemann, N
    Gonsch, T
    Weber, J
    Kleine-Tebbe, A
    Conrad, B
    Klare, P
    Hindenburg, HJ
    Ruhmland, B
    Lakner, V
    Hinke, A
    BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S94 - S95
  • [7] Targeted Therapies in HER2-Overexpressing Metastatic Breast Cancer
    Labidi, Soumaya
    Mejri, Nesrine
    Lagha, Aymen
    Daoud, Nouha
    El Benna, Houda
    Afrit, Mehdi
    Boussen, Hamouda
    BREAST CARE, 2016, 11 (06) : 418 - 422
  • [8] Effects of trastuzumab and paclitaxel in HER2-overexpressing breast cancer
    Li, Songhua
    Higuchi, Hideo
    Ohuchi, Noriaki
    FUTURE MEDICAL ENGINEERING BASED ON BIONANOTECHNOLOGY, PROCEEDINGS, 2006, : 395 - +
  • [9] Brain metastases in HER2-overexpressing metastatic breast cancer (MBC) patients (PTS)
    Gori, S.
    Rimondini, S.
    De Angelis, V.
    Sidoni, A.
    Mosconi, A. M.
    Aristei, C.
    Perrucci, E.
    Basurto, C.
    Franceschi, E.
    Scopece, L.
    Degli Esposti, R.
    Colozza, M.
    Crino, L.
    ANNALS OF ONCOLOGY, 2005, 16 : 10 - 11
  • [10] Weekly Gemcitabine and Trastuzumab in the Treatment of Patients With HER2-Overexpressing Metastatic Breast Cancer
    Yardley, Denise A.
    Burris, Howard A., III
    Hanson, Sarah
    Greco, F. Anthony
    Spigel, David R.
    Barton, John
    Hainsworth, John D.
    CLINICAL BREAST CANCER, 2009, 9 (03) : 178 - 183
12345